10. Business Segment, Product and Geographic Information

The Company’s business operates in one segment based upon the Company’s organizational structure, the way in which the operations are managed and evaluated and the lack of availability of separate financial results.

The Company’s spine surgery product line offerings, which include thoracolumbar product offerings, cervical offerings, and motion preservation products, are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologic product line offerings includes allograft (donated human tissue), FormaGraft^®, a collagen synthetic product, Osteocel Plus^®, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, and AttraX^®, a synthetic bone graft material, all used to aid the spinal fusion process. The Company’s monitoring service offering includes IOM services provided. Revenue by product line offerings was as follows (in thousands):



	Year Ended December 31,
	2013		2012		2011
Spine Surgery Products	$	530,370	$	471,186	$	430,970
Biologics	115,633		110,179		99,759
Monitoring Service	39,170		38,890		9,777
Total Revenue	$	685,173	$	620,255	$	540,506

Revenue and property and equipment, net, by geographic area were as follows (in thousands):



	Revenue						Property and Equipment, Net
	Year Ended December 31,						December 31,
	2013		2012		2011		2013		2012
United States	$	620,363	$	575,255	$	511,310	$	109,458	$	112,701
International (excludes Puerto Rico)	64,810		45,000		29,196		18,606		12,422
Total	$	685,173	$	620,255	$	540,506	$	128,064	$	125,123